SG10201907161YA - Antibodies directed against lymphocyte activation gene 3 (lag-3) - Google Patents
Antibodies directed against lymphocyte activation gene 3 (lag-3)Info
- Publication number
- SG10201907161YA SG10201907161YA SG10201907161YA SG10201907161YA SG10201907161YA SG 10201907161Y A SG10201907161Y A SG 10201907161YA SG 10201907161Y A SG10201907161Y A SG 10201907161YA SG 10201907161Y A SG10201907161Y A SG 10201907161YA SG 10201907161Y A SG10201907161Y A SG 10201907161YA
- Authority
- SG
- Singapore
- Prior art keywords
- lag
- lymphocyte activation
- activation gene
- chain polypeptide
- directed against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562111486P | 2015-02-03 | 2015-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201907161YA true SG10201907161YA (en) | 2019-09-27 |
Family
ID=56564868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907161YA SG10201907161YA (en) | 2015-02-03 | 2016-02-03 | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
| SG11201706199RA SG11201706199RA (en) | 2015-02-03 | 2016-02-03 | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706199RA SG11201706199RA (en) | 2015-02-03 | 2016-02-03 | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10836824B2 (fr) |
| EP (2) | EP4011914A1 (fr) |
| JP (1) | JP6949713B2 (fr) |
| KR (1) | KR20170116067A (fr) |
| CN (2) | CN107428836A (fr) |
| BR (1) | BR112017016638B1 (fr) |
| CA (1) | CA2975753A1 (fr) |
| EA (1) | EA201791742A1 (fr) |
| HK (2) | HK1246814A1 (fr) |
| IL (1) | IL253718B (fr) |
| MA (1) | MA41463A (fr) |
| MX (2) | MX2017009904A (fr) |
| NZ (1) | NZ734880A (fr) |
| SG (2) | SG10201907161YA (fr) |
| WO (1) | WO2016126858A2 (fr) |
| ZA (1) | ZA201705303B (fr) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
| UA124925C2 (en) | 2015-10-02 | 2021-12-15 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
| EP3471753A1 (fr) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 et cytokines il-2 |
| CN109689870B (zh) | 2016-09-08 | 2022-11-29 | 第一三共株式会社 | 用于治疗自身免疫疾病的抗体 |
| AU2017343621B2 (en) | 2016-10-11 | 2021-12-02 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
| MA46525A (fr) * | 2016-10-13 | 2019-08-21 | Symphogen As | Anticorps anti-lag-3 et compositions |
| US11155624B2 (en) | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| KR102606252B1 (ko) | 2017-01-09 | 2023-11-23 | 테사로, 인코포레이티드 | 항-pd-1 항체로 암을 치료하는 방법 |
| CN110382000A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗tim-3抗体治疗癌症的方法 |
| CN118557758A (zh) | 2017-02-10 | 2024-08-30 | 瑞泽恩制药公司 | 用于免疫-pet成像的放射性标记的抗-lag3抗体 |
| JP6929951B2 (ja) * | 2017-02-22 | 2021-09-01 | アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド | 抗ｌａｇ−３抗体およびその使用 |
| PE20191494A1 (es) | 2017-04-03 | 2019-10-21 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15 |
| CA3058960C (fr) | 2017-04-05 | 2023-08-29 | Symphogen A/S | Polytherapies ciblant pd-1, tim-3 et lag-3 |
| TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
| CA3053360A1 (fr) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Anticorps anti-lag3 |
| EP3615572A1 (fr) * | 2017-04-27 | 2020-03-04 | Tesaro Inc. | Agents anticorps dirigés contre la protéine codée par le gène d'activation des lymphocytes 3 (lag-3) et utilisations associées |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| MX2019012032A (es) | 2017-05-30 | 2019-10-30 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). |
| CA3060989A1 (fr) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprenant une combinaison d'un anticorps anti-lag-3, d'un inhibiteur de voie pd-1 et d'un agent immunotherapeutique |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| EP3675898A4 (fr) | 2017-08-30 | 2021-09-01 | Phanes Therapeutics, Inc. | Anticorps anti-lag-3 et leurs utilisations |
| AU2018341479B2 (en) | 2017-09-26 | 2022-02-17 | Tesaro, Inc. | Niraparib formulations |
| EP3697442A4 (fr) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | Polythérapies pour le traitement du cancer |
| CA3076859A1 (fr) | 2017-10-06 | 2019-04-11 | Tesaro, Inc. | Polyrherapies et leurs utilisations |
| CN111655730A (zh) | 2018-01-31 | 2020-09-11 | 豪夫迈·罗氏有限公司 | 包含与lag3结合的抗原结合位点的双特异性抗体 |
| TWI833738B (zh) * | 2018-03-20 | 2024-03-01 | 中國大陸商上海藥明生物技術有限公司 | 新型抗lag-3抗體多肽 |
| WO2019179365A1 (fr) | 2018-03-20 | 2019-09-26 | WuXi Biologics Ireland Limited | Nouveau polypeptide anticorps anti-lag-3 |
| CN110343178B (zh) * | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | 抗人lag-3单克隆抗体及其应用 |
| CN110615840A (zh) * | 2018-06-19 | 2019-12-27 | 信达生物制药(苏州)有限公司 | 全人源的抗lag-3抗体及其应用 |
| CN112119094A (zh) * | 2018-06-29 | 2020-12-22 | Y 生物股份有限公司 | 与淋巴细胞活化基因3特异性结合的单克隆抗体及其用途 |
| EP3826660A1 (fr) | 2018-07-26 | 2021-06-02 | Bristol-Myers Squibb Company | Polythérapie à base de lag-3 pour le traitement du cancer |
| WO2020051142A2 (fr) | 2018-09-04 | 2020-03-12 | Tesaro, Inc. | Méthodes de traitement du cancer |
| WO2020072797A1 (fr) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Sels de niraparib |
| CN113330007A (zh) | 2018-10-03 | 2021-08-31 | 特沙诺有限公司 | 尼拉帕利游离碱的晶体形式 |
| US20210338813A1 (en) | 2018-10-19 | 2021-11-04 | Bristol-Myers Squibb Company | Combination Therapy for Melanoma |
| WO2020243563A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales destinées à être adaptées à une thérapie immuno-oncologique |
| WO2020243570A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Signature de localisation cellulaire et polythérapie |
| EP3976832A1 (fr) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o) |
| CN112010972B (zh) * | 2019-05-31 | 2023-01-10 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
| WO2021024020A1 (fr) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer |
| WO2021055994A1 (fr) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Profilage spatial quantitatif pour une thérapie par antagoniste de lag-3 |
| WO2021092221A1 (fr) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle |
| WO2021092220A1 (fr) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle |
| AU2020380384A1 (en) | 2019-11-08 | 2022-05-26 | Bristol-Myers Squibb Company | LAG-3 antagonist therapy for melanoma |
| CA3164600A1 (fr) | 2019-12-18 | 2021-06-24 | Tesaro, Inc. | Compositions biopharmaceutiques et procedes associes |
| JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１０およびその使用 |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| JP2023538955A (ja) | 2020-08-31 | 2023-09-12 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在シグネチャーおよび免疫療法 |
| MX2023004493A (es) | 2020-10-23 | 2023-05-10 | Bristol Myers Squibb Co | Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon. |
| WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
| WO2022135667A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Arn thérapeutique pour le traitement du cancer |
| WO2022135666A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Programme de traitement faisant intervenir des protéines cytokines |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022146948A1 (fr) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Administration sous-cutanée d'anticorps pd1/pd-l1 |
| WO2022146947A1 (fr) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
| CN112852870B (zh) * | 2021-01-13 | 2022-03-04 | 北京鼎成肽源生物技术有限公司 | IL-18基因融合H2Kk基因在制备增强细胞免疫的细胞中的应用、细胞及制备方法 |
| CN114907478A (zh) * | 2021-02-08 | 2022-08-16 | 迈威(上海)生物科技股份有限公司 | 结合lag-3的抗体及其用途 |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| WO2022240741A1 (fr) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Agents inhibiteurs de lag3 et gal3, peptides xbp1, cs1 et cd138, et leurs méthodes d'utilisation |
| KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
| CN113603779B (zh) * | 2021-08-18 | 2023-06-02 | 深圳市元谷生物科技有限公司 | 一种结合人淋巴细胞活化基因3(lag-3)的抗体及其用途 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| MX2024005053A (es) | 2021-10-29 | 2024-05-10 | Bristol Myers Squibb Co | Terapia con antagonista del gen de activacion de linfocitos 3 (lag-3) para cancer hematologico. |
| MX2024008831A (es) | 2022-01-26 | 2024-07-25 | Bristol Myers Squibb Company | Terapia combinada para carcinoma hepatocelular. |
| AU2023226078A1 (en) | 2022-02-25 | 2024-08-22 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma. |
| WO2023168404A1 (fr) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Méthodes de traitement d'une tumeur |
| WO2023170606A1 (fr) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t |
| WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
| CN114874324B (zh) * | 2022-05-13 | 2023-02-03 | 苏州旭光科星抗体生物科技有限公司 | 一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用 |
| WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
| WO2024116140A1 (fr) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Polythérapie comprenant des anticorps anti-pd-l1 et anti-cd73 pour le traitement du cancer |
| WO2024126457A1 (fr) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et des inhibiteurs de point de contrôle immunitaire |
| WO2024137776A1 (fr) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Polythérapie contre le cancer du poumon |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| WO2024196952A1 (fr) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Évaluation de sous-type de tumeur pour une thérapie anticancéreuse |
| CN118275703B (zh) * | 2024-06-03 | 2024-08-23 | 军科正源（北京）药物研究有限责任公司 | 检测抗淋巴细胞激活基因3抗体药物中和抗体的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0557459B1 (fr) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Genes de fusion selectionnables bifonctionnels |
| EP0804590A1 (fr) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd) |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| JP3700859B2 (ja) * | 1994-05-06 | 2005-09-28 | アンスティテュ ギュスタブ ルシ | Ｌａｇ−３タンパク質の可溶性ポリペプチドフラクション；製造方法、治療用製剤、抗イディオタイプ抗体 |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| FI1897548T4 (fi) | 2003-02-28 | 2024-09-03 | The Johns Hopkins University | T-solujen säätely |
| EP2126105A4 (fr) | 2007-02-20 | 2010-11-03 | Anaptysbio Inc | Systèmes d'hypermutation somatique |
| EP1987839A1 (fr) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes |
| EP2044949A1 (fr) * | 2007-10-05 | 2009-04-08 | Immutep | Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| ES2743203T3 (es) * | 2012-02-06 | 2020-02-18 | Inhibrx Inc | Anticuerpos CD47 y métodos de uso de los mismos |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
| SG11201506727RA (en) | 2013-03-01 | 2015-09-29 | Astex Pharmaceuticals Inc | Drug combinations |
| KR101763352B1 (ko) * | 2013-03-15 | 2017-07-31 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 항ｌａｇ3 결합 단백질 |
| WO2015143343A2 (fr) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| WO2015179799A1 (fr) | 2014-05-22 | 2015-11-26 | The General Hospital Corporation | Récepteur dd1alpha et ses utilisations dans des troubles immunitaires |
| US20160176962A1 (en) | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| MX2022009355A (es) * | 2020-01-29 | 2022-09-02 | Kenjockety Biotechnology Inc | Anticuerpo anti-mdr1 y uso del mismo. |
-
2016
- 2016-02-02 MA MA041463A patent/MA41463A/fr unknown
- 2016-02-03 SG SG10201907161YA patent/SG10201907161YA/en unknown
- 2016-02-03 KR KR1020177024728A patent/KR20170116067A/ko not_active Application Discontinuation
- 2016-02-03 JP JP2017540834A patent/JP6949713B2/ja active Active
- 2016-02-03 WO PCT/US2016/016424 patent/WO2016126858A2/fr active Application Filing
- 2016-02-03 EA EA201791742A patent/EA201791742A1/ru unknown
- 2016-02-03 EP EP21198994.2A patent/EP4011914A1/fr active Pending
- 2016-02-03 BR BR112017016638-0A patent/BR112017016638B1/pt active IP Right Grant
- 2016-02-03 MX MX2017009904A patent/MX2017009904A/es unknown
- 2016-02-03 SG SG11201706199RA patent/SG11201706199RA/en unknown
- 2016-02-03 CN CN201680020117.3A patent/CN107428836A/zh active Pending
- 2016-02-03 CN CN202210381152.5A patent/CN114634573A/zh active Pending
- 2016-02-03 CA CA2975753A patent/CA2975753A1/fr active Pending
- 2016-02-03 US US15/548,405 patent/US10836824B2/en active Active
- 2016-02-03 EP EP16747220.8A patent/EP3253798A4/fr not_active Ceased
- 2016-02-03 NZ NZ734880A patent/NZ734880A/en unknown
-
2017
- 2017-07-30 IL IL253718A patent/IL253718B/en unknown
- 2017-07-31 MX MX2022000112A patent/MX2022000112A/es unknown
- 2017-08-04 ZA ZA2017/05303A patent/ZA201705303B/en unknown
-
2018
- 2018-05-17 HK HK18106454.6A patent/HK1246814A1/zh unknown
- 2018-05-25 HK HK18106890.8A patent/HK1247618A1/zh unknown
-
2019
- 2019-05-01 US US16/400,198 patent/US20190256596A1/en not_active Abandoned
-
2020
- 2020-10-19 US US17/074,269 patent/US20210095026A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL253718B (en) | 2021-08-31 |
| US20180127496A1 (en) | 2018-05-10 |
| EP3253798A2 (fr) | 2017-12-13 |
| HK1246814A1 (zh) | 2018-09-14 |
| HK1247618A1 (zh) | 2018-09-28 |
| MX2017009904A (es) | 2018-06-27 |
| EP4011914A1 (fr) | 2022-06-15 |
| MA41463A (fr) | 2017-12-12 |
| EA201791742A1 (ru) | 2018-01-31 |
| SG11201706199RA (en) | 2017-08-30 |
| WO2016126858A3 (fr) | 2016-09-29 |
| CA2975753A1 (fr) | 2016-08-11 |
| WO2016126858A2 (fr) | 2016-08-11 |
| NZ734880A (en) | 2024-07-05 |
| JP2018505674A (ja) | 2018-03-01 |
| US20210095026A1 (en) | 2021-04-01 |
| CN107428836A (zh) | 2017-12-01 |
| ZA201705303B (en) | 2022-12-21 |
| IL253718A0 (en) | 2017-09-28 |
| CN114634573A (zh) | 2022-06-17 |
| US10836824B2 (en) | 2020-11-17 |
| EP3253798A4 (fr) | 2018-07-25 |
| MX2022000112A (es) | 2022-02-10 |
| BR112017016638A2 (pt) | 2018-06-19 |
| JP6949713B2 (ja) | 2021-10-13 |
| BR112017016638B1 (pt) | 2023-11-07 |
| US20190256596A1 (en) | 2019-08-22 |
| KR20170116067A (ko) | 2017-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000112A (es) | Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3). | |
| MX2023001791A (es) | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). | |
| MX2019012793A (es) | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. | |
| ZA201706740B (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| MX2015015037A (es) | Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1). | |
| MX2020001272A (es) | Anticuerpos dirigidos contra interleucina-33 (il-33). | |
| MX2019005116A (es) | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). | |
| NZ738008A (en) | Tigit-binding agents and uses thereof | |
| SA519401370B1 (ar) | الأجسام المضادة وحيدة النسيلة المبتكرة لبروتين الموت المبرمج (pd-1) | |
| EA201990747A1 (ru) | Способы лечения иммунных нарушений с применением белков, связывающих pd–1 | |
| MX2019005117A (es) | Anticuerpos dirigidos contra la muerte programada 1 (pd-1). | |
| WO2018017864A3 (fr) | Agents de liaison à pvrig et leurs utilisations | |
| MX2018014979A (es) | Anticuerpos específicos dirigidos contra hla-g. | |
| MD4716C1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
| MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
| MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
| EP4218817A3 (fr) | Méthodes de traitement de maladies métaboliques par inhibition de l'activation de la myostatine | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| MX2020010092A (es) | Variantes de anticuerpo c-terminales. | |
| MX2020013923A (es) | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. | |
| WO2015116569A3 (fr) | Anticorps dirigés contre la famille des récepteurs à domaine discoïdine, élément 1 (ddr1) | |
| EA202092981A1 (ru) | Антитела к l1cam и их применение | |
| EA201992747A1 (ru) | Антитела к fam19a5 и их применение | |
| EA201890762A1 (ru) | Антитела к lag3 и их применения |